Phenatine

Phenatine
Clinical data
Trade names	Fenatine
Other names	Phenatin; Fenatin; Fenatine; Nicotinoylamphetamine; N-Nicotinoylamphetamine; N-Nicotinoyl-β-phenylisopropylamine; N-(α-Methylphenethyl)nicotinamide
Drug class	Psychostimulant; Amphetamine
Identifiers
	IUPAC name N-(1-phenylpropan-2-yl)pyridine-3-carboxamide;
CAS Number	139-68-4;
PubChem CID	120640;
ChemSpider	107702;
UNII	90O34W851E;
CompTox Dashboard (EPA)	DTXSID40930271 ;
Chemical and physical data
Formula	C15H16N2O
Molar mass	240.306 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(CC1=CC=CC=C1)NC(=O)C2=CN=CC=C2;
	InChI InChI=1S/C15H16N2O/c1-12(10-13-6-3-2-4-7-13)17-15(18)14-8-5-9-16-11-14/h2-9,11-12H,10H2,1H3,(H,17,18); Key:KJRJJAZBUWXZFN-UHFFFAOYSA-N;

Phenatine, or phenatin, also known as N-nicotinoylamphetamine and sold under the brand name Fenatine, is a psychostimulant of the amphetamine family which was developed and used in the Soviet Union.^[1]^[2]^[3]^[4]^[5]^[6]^[7] It was used in the treatment of depression, narcolepsy, post-encephalitis sequelae, alcoholic psychoses, asthenia, and other conditions.^[1]^[5]

^ ^a ^b Jablonski S, Leonard RM (1961). Russian Drug Index. Public Health Service publication. U.S. Department of Health, Education, and Welfare, Public Health Service. p. 40. Retrieved 29 September 2024 – via National Library of Medicine (U.S.).
^ Usdin E, Efron DH (1972). Psychotropic Drugs and Related Compounds (2nd ed.). National Institute of Mental Health. p. 285. Retrieved 29 September 2024.
^ Leake CD (1958). The Amphetamines: Their Actions and Uses. A monograph in the Bannerstone Division of American lectures in pharmacology. Thomas. p. 12. Retrieved 29 September 2024.
^ Grant WM (1974). Toxicology of the Eye: Drugs, Chemicals, Plants, Venoms. Thomas. p. 804. ISBN 978-0-398-02299-0. Retrieved 29 September 2024. Phenatin (Phenatine, nicotinic acid β-phenylisopropylamide, fenatin), an antidepressant stimulatory drug is reported to have altered the ability of the human eye to discriminate between orange-red and white when 20 mg was administered experimentally.
^ ^a ^b Dange SA, Adhikari GM (1963). International Socialist Miscellany (in Italian). Vol. 1. p. 131. Retrieved 29 September 2024. [...] would have no harmful side-effects. Such a drug has been produced. The staff of the chair of pharmacology of the Kirov Medical Officers College evolved, after thorough investigations, the preparation of phenatin. As to its effect and properties, phenatin is superior to all the existing stimulators of the nervous system. It was developed by Professor Sergey Arbuzov. This preparation, says the Professor, is a condensate of phenamin with nicotinic acid (Vitamin PP). It has a mild stimulating effect and simultaneously reduces the blood pressure. It can be used by people engaged in long and strenuous work and by people suffering from hypertensive disease. The preparation excites metabolism and can therefore successfully be used in obesity and old-age asthenia. Unlike phenamin, phenatin does not lead to the exhaustion of the nervous system, granted that there is no overdosage of the preparation. Our chair has also produced certain derivatives of phenatin which likewise possess valuable qualities. For instance, there is pyridoxiphen, a product of condensation of phenamin and pyridoxine (Vitamin B6). This preparation is necessary in clinical practice for treating some of the diseases of the nervous system. We are persistently looking for even more active stimulators. [...]
^ Problems of Space Biology. U.S. National Aeronautics and Space Administration. [for sale by Office of Technical Services, Department of Commerce.] 1973. pp. 343–344. Retrieved 29 September 2024. Phenatine is an original Soviet drug, obtained by condensing phenamine and nicotinic acid. Phenatine is much less toxic than phenamine; It is a gentler stimulant of the central nervous system. Unlike phenamlne, the drug has a hypotensive effect (Arbuzov, 1952, 1953, 1960; Makarov, 1958, and others). In this respect it can be prescribed in those cases when phenamine is contraindicated (for example, hypertonic disease, old age, asthenic syndrome, etc.). Phenatine stimulates mental and physical efficiency. Research conducted on man (Arbuzov, 1960) established that phenatine intensifies the excitatory process with brief concentration of the inhibitory process, maintaining the equilibrium of nerve processes at a higher level. The drug can intensify activity not only of the cortex of the large hemispheres, but also the subcortex. An important aspect of the drug is that its use is not accompanied by negative aftereffects; neither have cases of addiction to phenatine been noted. [...]
^ UN International Drug Control Programme (1996). "Amphetamine-type stimulants : a global review /: prepared by UNDCP at the request of the Commission on Narcotic Drugs". UN International Drug Control Programme. Retrieved 29 September 2024. Table 2: Licit use of controlled amphetamine-type substances in the manufacture of other pharmaceuticals: AMFETAMINE ("); [...] Product: phenatine; 1971 Convention: Schedule: -; optical isomer: -; Therapeutic category/Use of product: psychostimulant; isomer that is usually used: -; Conversion cases reportd (1990-1993): - [Merck Index, 1989].

[JablonskiLeonard1961-1] Jablonski S, Leonard RM (1961). Russian Drug Index. Public Health Service publication. U.S. Department of Health, Education, and Welfare, Public Health Service. p. 40. Retrieved 29 September 2024 – via National Library of Medicine (U.S.).

[NIMH1972-2] Usdin E, Efron DH (1972). Psychotropic Drugs and Related Compounds (2nd ed.). National Institute of Mental Health. p. 285. Retrieved 29 September 2024.

[Leake1958-3] Leake CD (1958). The Amphetamines: Their Actions and Uses. A monograph in the Bannerstone Division of American lectures in pharmacology. Thomas. p. 12. Retrieved 29 September 2024.

[Grant1974-4] Grant WM (1974). Toxicology of the Eye: Drugs, Chemicals, Plants, Venoms. Thomas. p. 804. ISBN 978-0-398-02299-0. Retrieved 29 September 2024. Phenatin (Phenatine, nicotinic acid β-phenylisopropylamide, fenatin), an antidepressant stimulatory drug is reported to have altered the ability of the human eye to discriminate between orange-red and white when 20 mg was administered experimentally.

[DangeAdhikari1963-5] Dange SA, Adhikari GM (1963). International Socialist Miscellany (in Italian). Vol. 1. p. 131. Retrieved 29 September 2024. [...] would have no harmful side-effects. Such a drug has been produced. The staff of the chair of pharmacology of the Kirov Medical Officers College evolved, after thorough investigations, the preparation of phenatin. As to its effect and properties, phenatin is superior to all the existing stimulators of the nervous system. It was developed by Professor Sergey Arbuzov. This preparation, says the Professor, is a condensate of phenamin with nicotinic acid (Vitamin PP). It has a mild stimulating effect and simultaneously reduces the blood pressure. It can be used by people engaged in long and strenuous work and by people suffering from hypertensive disease. The preparation excites metabolism and can therefore successfully be used in obesity and old-age asthenia. Unlike phenamin, phenatin does not lead to the exhaustion of the nervous system, granted that there is no overdosage of the preparation. Our chair has also produced certain derivatives of phenatin which likewise possess valuable qualities. For instance, there is pyridoxiphen, a product of condensation of phenamin and pyridoxine (Vitamin B6). This preparation is necessary in clinical practice for treating some of the diseases of the nervous system. We are persistently looking for even more active stimulators. [...]

[ProbSpaceBio1973-6] Problems of Space Biology. U.S. National Aeronautics and Space Administration. [for sale by Office of Technical Services, Department of Commerce.] 1973. pp. 343–344. Retrieved 29 September 2024. Phenatine is an original Soviet drug, obtained by condensing phenamine and nicotinic acid. Phenatine is much less toxic than phenamine; It is a gentler stimulant of the central nervous system. Unlike phenamlne, the drug has a hypotensive effect (Arbuzov, 1952, 1953, 1960; Makarov, 1958, and others). In this respect it can be prescribed in those cases when phenamine is contraindicated (for example, hypertonic disease, old age, asthenic syndrome, etc.). Phenatine stimulates mental and physical efficiency. Research conducted on man (Arbuzov, 1960) established that phenatine intensifies the excitatory process with brief concentration of the inhibitory process, maintaining the equilibrium of nerve processes at a higher level. The drug can intensify activity not only of the cortex of the large hemispheres, but also the subcortex. An important aspect of the drug is that its use is not accompanied by negative aftereffects; neither have cases of addiction to phenatine been noted. [...]

[UN-IDCP1996-7] UN International Drug Control Programme (1996). "Amphetamine-type stimulants : a global review /: prepared by UNDCP at the request of the Commission on Narcotic Drugs". UN International Drug Control Programme. Retrieved 29 September 2024. Table 2: Licit use of controlled amphetamine-type substances in the manufacture of other pharmaceuticals: AMFETAMINE ("); [...] Product: phenatine; 1971 Convention: Schedule: -; optical isomer: -; Therapeutic category/Use of product: psychostimulant; isomer that is usually used: -; Conversion cases reportd (1990-1993): - [Merck Index, 1989].

[1]

[2]

[3]

[4]

[5]

[6]

[7]